Gliclazide directly inhibits arginine-induced glucagon release.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Gliclazide directly inhibits arginine-induced glucagon release. / Cejvan, Kenan; Coy, David H; Holst, Jens Juul; Cerasi, Erol; Efendic, Suad.
In: Diabetes, Vol. 51 Suppl 3, 2002, p. S381-4.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Gliclazide directly inhibits arginine-induced glucagon release.
AU - Cejvan, Kenan
AU - Coy, David H
AU - Holst, Jens Juul
AU - Cerasi, Erol
AU - Efendic, Suad
N1 - Keywords: Animals; Arginine; Gliclazide; Glucagon; Islets of Langerhans; Male; Pancreas; Peptides, Cyclic; Rats; Rats, Wistar; Receptors, Somatostatin; Somatostatin; Sulfonylurea Compounds
PY - 2002
Y1 - 2002
N2 - Arginine-stimulated insulin and somatostatin release is enhanced by the sulfonylurea gliclazide. In contrast, gliclazide inhibits the glucagon response. The aim of the present study was to investigate whether this inhibition of glucagon release was mediated by a direct suppressive effect of gliclazide or was secondary to the paracrine effect of released somatostatin. To eliminate the paracrine effects of somatostatin, we first perfused isolated rat pancreata with a medium supplemented with 23% of the standard calcium content. Second, we perifused isolated rat islets with a novel and highly specific antagonist of type 2 somatostatin receptor, DC-41-33 (2 micro mol/l), which fully antagonizes the suppressive somatostatin effect on rat A cells. Gliclazide (30 micro mol/l) inhibited glucagon release by 54% in the perfusion experiments, whereas the somatostatin response was nearly abolished. In islet perifusions with DC-41-33, arginine-induced glucagon release was inhibited by 66%. We therefore concluded that gliclazide inhibits glucagon release by a direct action on the pancreatic A cell.
AB - Arginine-stimulated insulin and somatostatin release is enhanced by the sulfonylurea gliclazide. In contrast, gliclazide inhibits the glucagon response. The aim of the present study was to investigate whether this inhibition of glucagon release was mediated by a direct suppressive effect of gliclazide or was secondary to the paracrine effect of released somatostatin. To eliminate the paracrine effects of somatostatin, we first perfused isolated rat pancreata with a medium supplemented with 23% of the standard calcium content. Second, we perifused isolated rat islets with a novel and highly specific antagonist of type 2 somatostatin receptor, DC-41-33 (2 micro mol/l), which fully antagonizes the suppressive somatostatin effect on rat A cells. Gliclazide (30 micro mol/l) inhibited glucagon release by 54% in the perfusion experiments, whereas the somatostatin response was nearly abolished. In islet perifusions with DC-41-33, arginine-induced glucagon release was inhibited by 66%. We therefore concluded that gliclazide inhibits glucagon release by a direct action on the pancreatic A cell.
M3 - Journal article
C2 - 12475779
VL - 51 Suppl 3
SP - S381-4
JO - Diabetes
JF - Diabetes
SN - 0012-1797
ER -
ID: 8418296